These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 8313361)
1. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent. Watanabe N; Goodwin DA; Meares CF; McTigue M; Chaovapong W; Ransone CM; Renn O Cancer Res; 1994 Feb; 54(4):1049-54. PubMed ID: 8313361 [TBL] [Abstract][Full Text] [Related]
2. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823 [TBL] [Abstract][Full Text] [Related]
4. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule. Perico ME; Chinol M; Nacca A; Luison E; Paganelli G; Canevari S J Nucl Med; 2001 Nov; 42(11):1697-703. PubMed ID: 11696642 [TBL] [Abstract][Full Text] [Related]
5. Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Adams GP; DeNardo SJ; Deshpande SV; DeNardo GL; Meares CF; McCall MJ; Epstein AL Cancer Res; 1989 Apr; 49(7):1707-11. PubMed ID: 2493983 [TBL] [Abstract][Full Text] [Related]
6. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. Deshpande SV; Subramanian R; McCall MJ; DeNardo SJ; DeNardo GL; Meares CF J Nucl Med; 1990 Feb; 31(2):218-24. PubMed ID: 2107283 [TBL] [Abstract][Full Text] [Related]
7. Development of ELISA for detection of mercury based on specific monoclonal antibodies against mercury-chelate. Zhang Y; Li X; Liu G; Wang Z; Kong T; Tang J; Zhag P; Yang W; Li D; Liu L; Xie G; Wang J Biol Trace Elem Res; 2011 Dec; 144(1-3):854-64. PubMed ID: 21437665 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981 [TBL] [Abstract][Full Text] [Related]
9. Suppression of human anti-mouse idiotypic antibody responses in hu-PBL-SCID mice. Bitoh S; Lang GM; Sehon AH Hum Antibodies Hybridomas; 1993 Jul; 4(3):144-51. PubMed ID: 8357958 [TBL] [Abstract][Full Text] [Related]
10. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. DeNardo SJ; DeNardo GL; DeNardo DG; Xiong CY; Shi XB; Winthrop MD; Kroger LA; Carter P Clin Cancer Res; 1999 Oct; 5(10 Suppl):3213s-3218s. PubMed ID: 10541366 [TBL] [Abstract][Full Text] [Related]
11. Identification of important residues in metal-chelate recognition by monoclonal antibodies. Delehanty JB; Jones RM; Bishop TC; Blake DA Biochemistry; 2003 Dec; 42(48):14173-83. PubMed ID: 14640685 [TBL] [Abstract][Full Text] [Related]
12. Preparation of specific monoclonal antibodies (MAbs) against heavy metals: MAbs that recognize chelated cadmium ions. Zhu X; Xu L; Lou Y; Yu H; Li X; Blake DA; Liu F J Agric Food Chem; 2007 Sep; 55(19):7648-53. PubMed ID: 17715887 [TBL] [Abstract][Full Text] [Related]
13. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. Lees A; Morris SC; Thyphronitis G; Holmes JM; Inman JK; Finkelman FD J Immunol; 1990 Dec; 145(11):3594-600. PubMed ID: 2246504 [TBL] [Abstract][Full Text] [Related]
15. Selective antibodies to propranolol enantiomers produced from a new conjugate. Sahui-Gnassi A; Pham-Huy C; Galons H; Warnet JM; Claude JR; Duc HT Chirality; 1993; 5(6):448-54. PubMed ID: 8398604 [TBL] [Abstract][Full Text] [Related]
16. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435 [TBL] [Abstract][Full Text] [Related]
17. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides. Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958 [TBL] [Abstract][Full Text] [Related]
18. Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen. Chen ZJ; Yang H; Liu CC; Hirai S; Ferrone S Cancer Res; 1993 Jan; 53(1):112-9. PubMed ID: 8416734 [TBL] [Abstract][Full Text] [Related]
19. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803 [TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]